Teachers Retirement System of The State of Kentucky Has $1.38 Million Holdings in TG Therapeutics, Inc. $TGTX

Teachers Retirement System of The State of Kentucky decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 47.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 38,323 shares of the biopharmaceutical company’s stock after selling 34,641 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in TG Therapeutics were worth $1,384,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Royal Bank of Canada lifted its stake in TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after acquiring an additional 10,660 shares in the last quarter. NewEdge Advisors LLC grew its stake in TG Therapeutics by 9.6% during the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 665 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of TG Therapeutics by 5.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after purchasing an additional 14,689 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of TG Therapeutics by 2.8% during the second quarter. Envestnet Asset Management Inc. now owns 51,682 shares of the biopharmaceutical company’s stock worth $1,860,000 after purchasing an additional 1,422 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Down 0.5%

Shares of TGTX stock opened at $29.03 on Friday. The stock’s 50 day simple moving average is $29.70 and its 200 day simple moving average is $31.46. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.89 and a current ratio of 4.10. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 10.48 and a beta of 1.87.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The company had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. During the same quarter last year, the business earned $0.15 EPS. The company’s revenue for the quarter was up 78.0% on a year-over-year basis. As a group, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Company set FY2026 revenue guidance of approximately $875–$900 million, well above the consensus of ~$785 million, signaling stronger-than-expected sales/market uptake that could support valuation and near-term cash flow. (No EPS guidance was supplied alongside the revenue range.)
• Positive Sentiment: TG Therapeutics scheduled multiple BRIUMVI® (ublituximab) data presentations for relapsing MS at the American Academy of Neurology (AAN) 2026 meeting (Apr 18–22). New clinical or safety details released at AAN could serve as a catalyst for shares. TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at AAN 2026
• Neutral Sentiment: The company’s most recent quarterly report showed revenue roughly in line with estimates but an EPS miss (reported $0.14 vs. $0.35 consensus), and management did not provide explicit EPS guidance with the FY2026 revenue range — leaving clarity on near-term profitability limited.
• Negative Sentiment: HC Wainwright trimmed EPS forecasts across several periods (Q2 and Q3 2026 and FY2026–FY2030), lowering near- and longer-term profit expectations (e.g., FY2026 from $1.30 to $1.21 and small downgrades for FY2027–FY2030). These cuts can weigh on sentiment and compress upside until company results or clinical readouts confirm the revenue trajectory. Q4 EPS Estimates for TG Therapeutics Cut by HC Wainwright

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. reduced their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.